Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 2897 - 2904 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC7462 | ACET |
|
Potent and selective GluK1 (formerly GluR5) containing kainate receptor antagonist (IC50 = 7 nM) that displays selectivity over GluK2 (formerly GluR6) containing kainate, NMDA, AMPA and group I mGlu receptors. Reversibly blocks induction of NMDA receptor-independent long term potentiation (LTP) in vitro at nanomolar concentrations.
|
|
| BCC7463 | CP 80633 |
|
Selective inhibitor of phosphodiesterase type 4 (IC50 values are 1.9, > 100, > 100, > 100 and > 100 μM for human lung PDE4, lung PDE1, lung PDE2, heart PDE3 and platelet PDE-V respectively) that displays no significant PDE4 isozyme selectivity. Inhibits hydrolysis of cAMP in isolated human peripheral blood monocytes, eosinophils and T cells. Displays anti-inflammatory and bronchodilatory effects in vivo.
|
|
| BCC7464 | AG 045572 |
|
Selective gonadotropin-releasing hormone (GnRH) receptor antagonist (Ki values are 2.2, 3.8 and 6.0 nM for mouse, rat and human receptors respectively). Suppresses testosterone and luteinising hormone (LH) levels in vivo.
|
|
| BCC7465 | U 90042 |
|
GABA<sub>A</sub> receptor ligand that binds with comparable affinities to three receptor subtypes: <span class='symbol'>α</span><sub>1</sub><span class='symbol'>β</span><sub>2</sub><span class='symbol'>γ</span><sub>2</sub>, <span class='symbol'>α</span><sub>3</sub><span class='symbol'>β</span><sub>2</sub><span class='symbol'>γ</span><sub>2</sub> and <span class='symbol'>α</span><sub>6</sub><span class='symbol'>β</span><sub>2</sub><span class='symbol'>γ</span><sub>2</sub> (K<sub>i</sub> values are 7.8, 9.5 and 11.0 nM respectively). Potentiates GABA-induced chloride currents in <span class='symbol'>α</span><sub>6</sub><span class='symbol'>β</span><sub>2</sub><span class='symbol'>γ</span><sub>2</sub> receptors. Sedative/hypnotic compound.
|
|
| BCC7466 | U 89843A |
|
Positive allosteric modulator of GABA<sub>A</sub> receptors. Enhances GABA-induced Cl<sup>-</sup> currents in the <span class='symbol'>α</span><sub>1</sub><span class='symbol'>β</span><sub>2</sub><span class='symbol'>γ</span><sub>2</sub>, <span class='symbol'>α</span><sub>3</sub><span class='symbol'>β</span><sub>2</sub><span class='symbol'>γ</span><sub>2</sub> and <span class='symbol'>α</span><sub>6</sub><span class='symbol'>β</span><sub>2</sub><span class='symbol'>γ</span><sub>2</sub> subtypes. Causes sedation <em>in vivo</em> following i.v. administration without losing "righting reflex". Also displays antioxidant activity.
|
|
| BCC7467 | PNU 96415E |
|
Antipsychotic agent. Displays high affinity for dopamine D<sub>4</sub> and serotonergic 5-HT<sub>2A</sub> receptors and relatively weak affinity at D<sub>2</sub> receptors (K<sub>i</sub> values are 3.0, 5.8, 134, 181, 199, 240, 411 and > 678 nM for D<sub>4</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>1A</sub>, <span class='symbol'>α</span><sub>1</sub>, D<sub>2</sub>, D<sub>3</sub>, D<sub>1</sub>, <span class='symbol'>α</span><sub>2</sub> and muscarinic receptors respectively). Inhibits exploratory locomotor activity and antagonizes d-amphetamine-induced locomotor stimulation in rats.
|
|
| BCC7468 | Sazetidine A dihydrochloride |
|
Subtype-selective <span class='symbol'>α</span>4<span class='symbol'>β</span>2 nicotinic acetylcholine receptor ligand (K<sub>i</sub> values are 0.26 and 54 nM at <span class='symbol'>α</span>4<span class='symbol'>β</span>2 and <span class='symbol'>α</span>3<span class='symbol'>β</span>4 receptors respectively). May act as a silent desensitizer or as an agonist, depending on subunit stoichiometry (EC<sub>50</sub> = 1.1 nM for nAChR-stimulated dopamine release). Exhibits analgesic activity <em>in vivo</em> and significantly reduces nicotine self-administration in an experimental rat model.
|
|
| BCC7469 | TC 2559 difumarate |
|
Subtype-selective partial agonist for <span class='symbol'>α</span>4<span class='symbol'>β</span>2 nicotinic acetylcholine receptors (EC<sub>50</sub> values are 0.18, 12.5, 14.0, > 30, > 100 and > 100 <span class='symbol'>μ</span>M for <span class='symbol'>α</span>4<span class='symbol'>β</span>2, <span class='symbol'>α</span>4<span class='symbol'>β</span>4, <span class='symbol'>α</span>2<span class='symbol'>β</span>4, <span class='symbol'>α</span>3<span class='symbol'>β</span>4, <span class='symbol'>α</span>3<span class='symbol'>β</span>2 and <span class='symbol'>α</span>7 receptor subtypes respectively). Displays selectivity for (<span class='symbol'>α</span>4)<sub>2</sub>(<span class='symbol'>β</span>2)<sub>3</sub> receptor stoichiometry and enhanced CNS-PNS selectivity ratio. Attenuates scopolamine-induced cognitive deficits in a step-through passive avoidance task.
|
|